Reviews/Polyphenols and Antioxidants/Cocoa flavanols improve endothelial function
CV · POLY-CV-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across sixteen randomised trials, drinking cocoa flavanols repeatedly made blood vessels relax and widen better, a response measured by flow-mediated dilation. This held in heart-disease patients [1], healthy young and older people [4], and patients on dialysis [11], and more flavanol tended to produce more effect [8]. The improvement also showed up when the researchers isolated the specific component thought to be active [12]. One trial in overweight adults found no change on this particular measure [5], and many trials were small and run by overlapping research groups. The panel judged the direction consistent and directly on point for the claim, while noting these limits keep it from being stated more strongly.
Every trial in the corpus measured endothelial function as flow-mediated dilation under a cocoa-flavanol intervention, and most show improvement or preservation: a 47% FMD gain in coronary patients [1], a 1.2% gain over control in healthy middle-aged adults [3], improvement in both young and elderly groups at p<0.001 [4], and acute (+53%) and chronic (+18%) gains in haemodialysis patients [11]. The effect was intake-dependent [8], and a parallel trial isolating the monomer fraction (DP1-10) increased FMD as its primary endpoint while the procyanidin fraction did not [12]. Flavanols also blunted FMD declines provoked by hyperglycaemia [6], mental stress [13], a high-fat meal [14], and prolonged sitting [15][16]. The single exception reported FMD and reactive hyperaemia index unchanged in overweight adults, alongside improvements in conduit-artery diameter and flow [5]. The contested point: The division is whether the effect is universal: [5] found FMD unchanged in overweight adults even as other vascular measures improved, against a strong positive signal elsewhere. The panel treated this as a genuine but minor inconsistency that tempers rather than reverses the direction.
All 16 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Polyphenols and Antioxidants, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
A direct null exists: [5] reports FMD and reactive hyperaemia index 'remained unchanged' in overweight adults, so the effect is not universal across populations.
Several trials are small (N=12-47: [1][6][7][8][9]), and small crossover studies are prone to overestimated effect sizes.
Where it remains uncertain. One trial found FMD unchanged in overweight adults [5], and several positive trials are small and share authors or the FLAVIOLA consortium ([3][4][7][8][12]).
The load-bearing papers from a corpus of 16, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Large relative FMD improvement in a double-masked crossover RCT in CAD patients.
“Endothelium-dependent vasomotor function, as measured by flow-mediated vasodilation of the brachial artery, improved by 47% in the HiFI period compared with the LoFI period.”
Panel auditInternal validity: medium · scope of inference: Older patients with coronary artery disease on guideline medical therapy.Key limitations: very small sample · surrogate endpoint · CAD-only population
Primary-endpoint FMD improvement in 100 healthy adults with a tight confidence interval.
“At 1 month, CF increased FMD over control by 1·2 % (95 % CI 1·0, 1·4 %).”
Panel auditInternal validity: high · scope of inference: Low-risk healthy middle-aged adults without CVD.Key limitations: surrogate endpoints · 1-month duration · low-risk population only
Improvement across age groups, extending generality to healthy populations.
“Following 2 weeks of CF intake, FMD improved in young (6.1 ± 0.7 vs. 7.6 ± 0.7 %, p < 0.001) and elderly (4.9 ± 0.6 vs. 6.3 ± 0.9 %, p < 0.001).”
Panel auditInternal validity: high · scope of inference: Healthy male non-smokers, young and elderly, without CVD.Key limitations: males only · 14-day duration · surrogate endpoint
FMD improvement plus protection against hyperglycaemia-induced endothelial impairment.
“Compared with white chocolate, dark chocolate ingestion improved flow-mediated dilation (P=0.03), wave reflections, endothelin-1 and 8-iso-PGF(2α) (P<0.05).”
Panel auditInternal validity: low · scope of inference: Young healthy volunteers, acute pre-treatment before a glucose load.Key limitations: very small sample · acute design · chocolate not isolated flavanol
4 of 16 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, mechanistically coherent, dose-responsive RCT evidence directly on the measured endpoint clears the Established band at its lower edge, held back from higher by surrogate-marker reliance, small N and incomplete independence.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent replication outside recurring groups. Several positive trials share authors or the FLAVIOLA consortium ([3][4][7][8][12]), raising independence and sponsorship concerns. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Adequately powered RCT measuring FMD under cocoa flavanols run by investigators with no consortium or industry ties.
Open question: Does cocoa-flavanol improvement in FMD persist beyond a few weeks of intake? Why it is still open: Corpus measurements run only 2h to 4 weeks [6][7][8][10], so durability is untested.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19